ArticleACS chemical biology2014
Optimal aggregation of FcεRI with a structurally defined trivalent ligand overrides negative regulation driven by phosphatases.
Article in ACS chemical biology, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 30 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
30 citing papers in PubMed, 42 citations in OpenAlex.
- IgE Occupancy and Antigen Valency Cooperate to Control FcεRI Aggregation Geometry and Signaling Efficiency.International journal of molecular sciences · 2026Article
- IgE occupancy and antigen valency cooperate to control FcεRI aggregation geometry and signaling efficiency.bioRxiv : the preprint server for biology · 2025Article
- Antigen properties shape organization of FcεRI aggregates to tune mast cell signaling.bioRxiv : the preprint server for biology · 2025Article
- Aberrant Activation of Mast Cells: Molecular Mechanisms and Targets for Intervention.Clinical reviews in allergy & immunology · 2025Review
- Successful Desensitization to Sorafenib and Imatinib-A Report of Two Cases and a Literature Review.Healthcare (Basel, Switzerland) · 2024Article
- Hapten-Decorated DNA Nanostructures Decipher the Antigen-Mediated Spatial Organization of Antibodies Involved in Mast Cell Activation.ACS nano · 2023Article
- Multistep IgE Mast Cell Desensitization Is a Dose- and Time-Dependent Process Partially Regulated by SHIP-1.Journal of immunology (Baltimore, Md. : 1950) · 2023Article
- Spatial requirements for ITAM signaling in an intracellular natural killer cell model membrane.Biochimica et biophysica acta. General subjects · 2022Article
- Docking of Syk to FcεRI is enhanced by Lyn but limited in duration by SHIP1.Molecular biology of the cell · 2022Article
- Review
- Temporal Modulation of Drug Desensitization Procedures.Current issues in molecular biology · 2022Review
- Desensitization for the prevention of drug hypersensitivity reactions.The Korean journal of internal medicine · 2022Review
- Regulation of Trafficking and Signaling of the High Affinity IgE Receptor by FcεRIβ and the Potential Impact of FcεRIβ Splicing in Allergic Inflammation.International journal of molecular sciences · 2022Review
- Insulin-regulated aminopeptidase contributes to setting the intensity of FcR-mediated inflammation.Frontiers in immunology · 2022Article
- Nutraceutical Aid for Allergies - Strategies for Down-Regulating Mast Cell Degranulation.Journal of asthma and allergy · 2021Review
- Case Report: Maintenance of Desensitization to Nebulized Colomycin Over 10 Years.Frontiers in pediatrics · 2021Article
- Interplay between Affinity and Valency in Effector Cell Degranulation: A Model System with Polcalcin Allergens and Human Patient-Derived IgE Antibodies.Journal of immunology (Baltimore, Md. : 1950) · 2019Article
- Article
- Combinatorial diversity of Syk recruitment driven by its multivalent engagement with FcεRIγ.Molecular biology of the cell · 2019Article
- A spatio-temporal model reveals self-limiting FcRoyal Society open science · 2018Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors at 3 institutions in 1 country.
Funding
Abstract
To investigate why responses of mast cells to antigen-induced IgE receptor (FcεRI) aggregation depend nonlinearly on antigen dose, we characterized a new artificial ligand, DF3, through complementary modeling and experimentation. This ligand is a stable trimer of peptides derived from bacteriophage T4 fibritin, each conjugated to a hapten (DNP). We found low and high doses of DF3 at which degranulation of mast cells sensitized with DNP-specific IgE is minimal, but ligand-induced receptor aggregation is comparable to aggregation at an intermediate dose, optimal for degranulation. This finding makes DF3 an ideal reagent for studying the balance of negative and positive signaling in the FcεRI pathway. We find that the lipid phosphatase SHIP and the protein tyrosine phosphatase SHP-1 negatively regulate mast cell degranulation over all doses considered. In contrast, SHP-2 promotes degranulation. With high DF3 doses, relatively rapid recruitment of SHIP to the plasma membrane may explain the reduced degranulation response. Our results demonstrate that optimal secretory responses of mast cells depend on the formation of receptor aggregates that promote sufficient positive signaling by Syk to override phosphatase-mediated negative regulatory signals.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.